Cardiovascular Research Advance Access first published online on January 29, 2009
This version [Corrected Proof] published online on February 24, 2009
Cardiovascular Research, doi:10.1093/cvr/cvp031
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling

Cardiovascular Division, School of Medicine, King's College London, London, UK
* Corresponding author: Cardiovascular Division, School of Medicine, King's College London, Franklin-Wilkins Building (Room 3.01), 150 Stamford Street, London SE1 9NH, UK. Tel: +44 20 7848 4306; fax: +44 20 7848 4500. E-mail address: giovanni.mann{at}kcl.ac.uk
Oxidative stress mediated by hyperglycaemia-induced generation of reactive oxygen species (ROS) contributes significantly to the development and progression of diabetes and related vascular complications. NAD(P)H oxidase has been implicated as the major source of ROS generation in the vasculature in response to high glucose and advanced glycation end-products. Sustained activation of NAD(P)H oxidase in diabetes may diminish intracellular levels of NADPH, an essential cofactor for endothelial NO synthase (eNOS) and several antioxidant systems. Recent evidence suggests that basal ROS production via NAD(P)H oxidase may upregulate antioxidant enzyme defenses via redox signalling. Thus, NAD(P)H oxidase may serve as a double-edged sword, with transient activation providing a feedback defense against excessive ROS generation through the activation of receptor tyrosine kinases and the redox-sensitive Nrf2-Keap1 signalling pathway. Overproduction of ROS leads to eNOS uncoupling, mitochondrial dysfunction, and impaired antioxidant defenses owing to depletion of intracellular NADPH. Given the largely negative outcome of antioxidant therapy in the treatment of diabetic complications, targeting the redox-sensitive transcription factor Nfr2 may provide an effective strategy to restore antioxidant defenses in diabetes.
KEYWORDS Diabetes; Endothelium; NAD(P)H oxidase; Mitochondria; eNOS; Redox signalling; Nrf2-Keap1 signalling; Antioxidant defense genes
Time for primary review: 23 days
Present address. Division of Molecular Medicine, Cardiovascular Research Laboratories, Departments of Anesthesiology and Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
D. Xiao, S. Yang, and L. Zhang Prenatal Cocaine Exposure Causes Sex-Dependent Impairment in the Myogenic Reactivity of Coronary Arteries in Adult Offspring Hypertension, November 1, 2009; 54(5): 1123 - 1128. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Fasanaro, M. C. Capogrossi, and F. Martelli Regulation of the endothelial cell cycle by the ubiquitin-proteasome system Cardiovasc Res, August 7, 2009; (2009) cvp244v2. [Abstract] [Full Text] [PDF] |
||||

